Trial
NCT02862145
Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions
Phase IWITHDRAWNSAFETYConfidence: HIGH
Sponsor
Mirna Therapeutics, Inc.
Collaborators
—
Condition
Melanoma
Intervention
MRX34
Why stopped
5 immune related serious adverse events in Phase 1 study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-09-27